Finerenone: Who should prescribe it for CKD?
Author Information
Author(s): Becky M. Ness, Heidi Webb
Primary Institution: Mayo Clinic College of Medicine
Hypothesis
How can physician associates be empowered to prescribe finerenone for chronic kidney disease (CKD) patients?
Conclusion
Empowering physician associates in the management of diabetic kidney disease can improve patient outcomes and reduce the burden of chronic kidney disease.
Supporting Evidence
- Finerenone reduced cardiovascular outcomes by 14% and kidney outcomes by 23% compared to placebo.
- Physician associates can monitor kidney function and encourage patient self-management.
- Early detection and management of CKD can prevent kidney failure and cardiovascular events.
Takeaway
This study shows that physician associates can help patients with kidney disease by prescribing important medications and monitoring their health.
Methodology
The study reviews existing literature and clinical trials related to finerenone and its effects on CKD.
Potential Biases
Potential bias in prescribing patterns among primary care providers versus specialists.
Limitations
The study may not account for all variables affecting CKD management in diverse populations.
Participant Demographics
Adults with type 2 diabetes and chronic kidney disease.
Statistical Information
P-Value
p<0.05
Confidence Interval
0.73–0.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website